Alkermes plc buy melinda
Start price
19.06.17
/
50%
€57.15
Target price
05.07.17
€60.00
Performance (%)
5.28%
End price
05.07.17
€60.17
Summary
This prediction ended on 05.07.17 with a price of €60.17. With a performance of 5.28%, the BUY prediction by melinda for Alkermes plc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 5.882% | 5.882% | -8.029% | 3.448% |
| iShares Core DAX® | 2.331% | 5.140% | 25.000% | 65.619% |
| iShares Nasdaq 100 | 2.077% | 2.956% | 8.935% | 111.545% |
| iShares Nikkei 225® | 2.759% | 7.214% | 22.171% | 56.683% |
| iShares S&P 500 | 1.613% | 2.893% | 6.249% | 68.722% |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.